TY - JOUR
T1 - Designing a large prevention trial
T2 - Statistical issues
AU - Kryscio, Richard J.
AU - Mendiondo, Marta S.
AU - Schmitt, Frederick A.
AU - Markesbery, William R.
PY - 2004/1/30
Y1 - 2004/1/30
N2 - Recent research in Alzheimer's disease (AD) is centred about the early detection and prevention of this disease. Several recent moderate size clinical trials targeted at high risk cohorts have been designed along this theme. There have been few attempts to design a large trial to prevent this disease in elderly individuals at low risk for the disease. The purpose of this paper is to suggest a framework for designing a simple, large AD prevention trial. This framework uses a discrete time hazard model for decreasing the incidence of AD when participants are randomly assigned to one or more active prevention agents or placebo. This design allows for differential incidence among participants due to age, family history, genetic disposition, and ethnicity. It takes into account the length of the follow-up period, participant mortality, drop-outs, drop-ins, and loss to follow-up. This framework is illustrated by PREADVISE, a recently initiated large add-on prevention trial investigating the use of anti-oxidants for preventing AD among men enrolled in a even larger prostate cancer prevention study, SELECT.
AB - Recent research in Alzheimer's disease (AD) is centred about the early detection and prevention of this disease. Several recent moderate size clinical trials targeted at high risk cohorts have been designed along this theme. There have been few attempts to design a large trial to prevent this disease in elderly individuals at low risk for the disease. The purpose of this paper is to suggest a framework for designing a simple, large AD prevention trial. This framework uses a discrete time hazard model for decreasing the incidence of AD when participants are randomly assigned to one or more active prevention agents or placebo. This design allows for differential incidence among participants due to age, family history, genetic disposition, and ethnicity. It takes into account the length of the follow-up period, participant mortality, drop-outs, drop-ins, and loss to follow-up. This framework is illustrated by PREADVISE, a recently initiated large add-on prevention trial investigating the use of anti-oxidants for preventing AD among men enrolled in a even larger prostate cancer prevention study, SELECT.
KW - Aging
KW - Alzheimer's disease
KW - Clinical trials
KW - Dementia
KW - Preventive
KW - Sample size
UR - http://www.scopus.com/inward/record.url?scp=0346463189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346463189&partnerID=8YFLogxK
U2 - 10.1002/sim.1716
DO - 10.1002/sim.1716
M3 - Article
C2 - 14716729
AN - SCOPUS:0346463189
SN - 0277-6715
VL - 23
SP - 285
EP - 296
JO - Statistics in Medicine
JF - Statistics in Medicine
IS - 2
ER -